Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis. (Q53463534)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

title

Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Thaer Khoury

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

Kazunori Kanehira

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

Dan Wang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

Wilfrido Mojica

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

Richard Cheney

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

Carl Morrison

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

Jeffrey Conroy

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

Norma Nowak

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

Song Liu

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

publication date

23 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

1364-1378

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20657551 AND SRC:MED&resulttype=core&format=json

Untangling the ErbB signalling network

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

HER-2 testing in breast cancer using parallel tissue-based methods

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Herceptin: mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Bioconductor: open software development for computational biology and bioinformatics

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

lumi: a pipeline for processing Illumina microarray

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Linear models and empirical bayes methods for assessing differential expression in microarray experiments

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Cluster analysis and display of genome-wide expression patterns

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

New approaches to antibody therapy

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy.

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Muc4/sialomucin complex in the mammary gland and breast cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021

Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2010.125

7 January 2021